{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:39:57Z","timestamp":1793756397192,"version":"4.6.1"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.intimp.2025.115429","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T08:56:45Z","timestamp":1756630605000},"page":"115429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Advancing insights into psoriasis: from pathogenesis to current and emerging therapies"],"prefix":"10.1016","volume":"165","author":[{"given":"Maria Beatriz S.","family":"Gon\u00e7alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Mascarenhas-Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Figueiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.115429_bb0005","series-title":"Taylor and Kelly\u2019s Dermatology for Skin of Color, 2e","article-title":"Psoriasis","author":"Geng","year":"2016"},{"key":"10.1016\/j.intimp.2025.115429_bb0010","series-title":"Pulmonary Manifestations of Primary Immunodeficiency Diseases","author":"Mahdaviani","year":"2019"},{"issue":"3","key":"10.1016\/j.intimp.2025.115429_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030739","article-title":"Advances in understanding the immunological pathways in psoriasis","volume":"20","author":"Georgescu","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2025.115429_bb0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/pharmaceutics16020239","article-title":"New and emerging oral\/topical small-molecule treatments for psoriasis","volume":"16","author":"Carmona-Rocha","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.intimp.2025.115429_bb0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.gene.2018.09.042","article-title":"Genomic alterations driving psoriasis pathogenesis","volume":"683","author":"Singh","year":"2019","journal-title":"Gene"},{"key":"10.1016\/j.intimp.2025.115429_bb0030","series-title":"Fitzpatrick\u2019s Dermatology, 9e","author":"Kang","year":"2019"},{"key":"10.1016\/j.intimp.2025.115429_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122991","article-title":"Advances in psoriasis research: from pathogenesis to therapeutics","volume":"355","author":"Sugumaran","year":"2024","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.intimp.2025.115429_bb0040","first-page":"375","article-title":"Back to the future: a new topical approach for mild-to-moderate psoriasis","volume":"153","author":"Girolomoni","year":"2018","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2025.115429_bb0045","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/PTT.S365493","article-title":"Efficacy and safety of anti-TNF biosimilars for psoriasis in pediatric and geriatric populations: a 72-week real-life study","volume":"12","author":"Megna","year":"2022","journal-title":"Psoriasis: Targ. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2025.115429_bb0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/14728214.2020.1745773","article-title":"Emerging systemic drugs in the treatment of plaque psoriasis","volume":"25","author":"Balogh","year":"2020","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"May","key":"10.1016\/j.intimp.2025.115429_bb0055","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.biopha.2018.06.136","article-title":"Emerging landscape in psoriasis management: from topical application to targeting biomolecules","volume":"106","author":"Rapalli","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.intimp.2025.115429_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2025.115429_bb0065","first-page":"369","article-title":"Review article: treatment of psoriasis","volume":"11","author":"Kilmer","year":"2010","journal-title":"Journalism Theor. Pract. Crit."},{"key":"10.1016\/j.intimp.2025.115429_bb0070","unstructured":"Psoriasis y S. Psoriasis en placas o vulgar - Causas, s\u00edntomas y tratamientos. 2014."},{"issue":"2","key":"10.1016\/j.intimp.2025.115429_bb0075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000495291","article-title":"Psoriasis: keratinocytes or immune cells - which is the trigger?","volume":"235","author":"Benhadou","year":"2019","journal-title":"Dermatology"},{"issue":"12","key":"10.1016\/j.intimp.2025.115429_bb0080","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1172\/JCI200422147","article-title":"Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities","volume":"113","author":"Nickoloff","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.intimp.2025.115429_bb0085","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12016-017-8634-3","article-title":"Unmet needs in the field of psoriasis: pathogenesis and treatment","volume":"55","author":"Boehncke","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.intimp.2025.115429_bb0090","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.genhosppsych.2022.01.006","article-title":"Associations between psoriasis and mental illness: an update for clinicians","volume":"75","author":"Hedemann","year":"2022","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.intimp.2025.115429_bb0095","series-title":"Corticoster\u00f3ides T\u00f3picos, considera\u00e7\u00f5es sobre a sua aplica\u00e7\u00e3o","author":"Leal Sofia","year":"2015"},{"key":"10.1016\/j.intimp.2025.115429_bb0100","unstructured":"\u00cdndice. Tazaroteno - Informa\u00e7\u00e3o Geral | INDICE.eu - Toda a Sa\u00fade. 2019."},{"issue":"9","key":"10.1016\/j.intimp.2025.115429_bb0105","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/17425255.2018.1515198","article-title":"Pharmacokinetics of tazarotene and acitretin in psoriasis","volume":"14","author":"Heath","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115429_bb0110","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/09546634.2017.1369494","article-title":"Review of the mechanism of action of coal tar in psoriasis","volume":"29","author":"Sekhon","year":"2018","journal-title":"J. Dermatolog. Treat."},{"issue":"6","key":"10.1016\/j.intimp.2025.115429_bb0115","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/1744666X.2020.1776116","article-title":"Calcipotriol\/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data","volume":"16","author":"Megna","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115429_bb0120","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/14712598.2018.1504016","article-title":"An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly","volume":"18","author":"Di Lernia","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2025.115429_bb0125","series-title":"RESUMO DAS CARACTER\u00cdSTICAS DO MEDICAMENTO","author":"Infarmed","year":"2020"},{"issue":"12","key":"10.1016\/j.intimp.2025.115429_bb0130","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/17512433.2018.1548277","article-title":"Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis","volume":"11","author":"Stiff","year":"2018","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115429_bb0135","series-title":"RESUMO DAS CARACTER\u00cdSTICAS DO MEDICAMENTO","author":"Infarmed","year":"2019"},{"issue":"5","key":"10.1016\/j.intimp.2025.115429_bb0140","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/09546634.2017.1398393","article-title":"Drug survival of biologic treatments in psoriasis: a systematic review","volume":"29","author":"No","year":"2018","journal-title":"J. Dermatolog. Treat."},{"issue":"6","key":"10.1016\/j.intimp.2025.115429_bb0145","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14740338.2019.1614561","article-title":"A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data","volume":"18","author":"Kolli","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.intimp.2025.115429_bb0150","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/09546634.2018.1427205","article-title":"The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis","volume":"29","author":"Sawyer","year":"2018","journal-title":"J. Dermatolog. Treat."},{"issue":"5","key":"10.1016\/j.intimp.2025.115429_bb0155","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/09546634.2017.1402116","article-title":"A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis","volume":"29","author":"No","year":"2018","journal-title":"J. Dermatolog. Treat."},{"issue":"3","key":"10.1016\/j.intimp.2025.115429_bb0160","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3390\/biom11030371","article-title":"The effect of herbal medicinal products on psoriasis-like keratinocytes","volume":"11","author":"Gendrisch","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.intimp.2025.115429_bb0165","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2147\/JEP.S265632","article-title":"Experimental pharmacological management of psoriasis","volume":"13","author":"Campione","year":"2021","journal-title":"J. Exp. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115429_bb0170","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/14712598.2020.1812576","article-title":"Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars","volume":"21","author":"Prignano","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2025.115429_bb0175","doi-asserted-by":"crossref","first-page":"2402912","DOI":"10.1080\/09546634.2024.2402912","article-title":"A review of biosimilars in psoriasis: impacts on efficacy, safety, access, and a first-hand look at biosimilar cost savings within the department of veterans affairs","volume":"35","author":"Reese","year":"2024","journal-title":"J. Dermatol. Treat."},{"issue":"1","key":"10.1016\/j.intimp.2025.115429_bb0180","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/14712598.2020.1798924","article-title":"Biosimilars in psoriasis: what should your positioning be?","volume":"21","author":"Ruiz-Villaverde","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2025.115429_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctim.2025.103173","article-title":"Herbal medicine for treating psoriasis: a systematic review","volume":"90","author":"Anheyer","year":"2025","journal-title":"Complement. Ther. Med."},{"key":"10.1016\/j.intimp.2025.115429_bb0190","article-title":"Benefits and safety of Chinese herbal medicine in treating psoriasis: an overview of systematic reviews","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115429_bb0195","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3390\/biomedicines10020228","article-title":"Novel therapeutic approaches to psoriasis and risk of infectious disease","volume":"10","author":"Motolese","year":"2022","journal-title":"Biomedicines"},{"issue":"17","key":"10.1016\/j.intimp.2025.115429_bb0200","doi-asserted-by":"crossref","first-page":"13313","DOI":"10.3390\/ijms241713313","article-title":"Challenges and future trends in the treatment of psoriasis","volume":"24","author":"Lee","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.115429_bb0205","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","article-title":"Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II\/III clinical studies in psoriasis and psoriatic arthritis","volume":"47","author":"Strober","year":"2024","journal-title":"Drug Saf."},{"key":"10.1016\/j.intimp.2025.115429_bb0210","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2147\/CCID.S364640","article-title":"Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence","author":"Ruggiero","year":"2022","journal-title":"Clin. Cosmet. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2025.115429_bb0215","unstructured":"SKYRIZI\u00ae (risankizumab-rzaa) injection, for subcutaneous use 2019 [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761105s014lbl.pdf."},{"key":"10.1016\/j.intimp.2025.115429_bb0220","unstructured":"ILUMYA\u2122 (tildrakizumab-asmn) injection, for subcutaneous use 2018 [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761067s000lbl.pdf."},{"issue":"2","key":"10.1016\/j.intimp.2025.115429_bb0225","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40257-019-00435-9","article-title":"Tildrakizumab: a review in moderate-to-severe plaque psoriasis","volume":"20","author":"Frampton","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115429_bb0230","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/14712598.2024.2325547","article-title":"Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden","volume":"24","author":"Dapavo","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2025.115429_bb0235","first-page":"13","article-title":"New and emerging oral therapies for psoriasis","author":"Yilmaz","year":"2024","journal-title":"Drugs Context"},{"issue":"1","key":"10.1016\/j.intimp.2025.115429_bb0240","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/pharmaceutics16010111","article-title":"Emerging oral therapies for the treatment of psoriasis: a review of pipeline agents","volume":"16","author":"Drakos","year":"2024","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.intimp.2025.115429_bb0245","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s13555-022-00746-6","article-title":"Narrative review of the emerging therapeutic role of brodalumab in difficult-to-treat psoriasis","volume":"12","author":"Menter","year":"2022","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.intimp.2025.115429_bb0250","unstructured":"Study on the Effectiveness and Safety of DC-806 for Adults with Moderate to Severe Plaque Psoriasis [cited 2025 04\/02 at 23 pm]. Available from: https:\/\/clinicaltrials.eu\/trial\/study-on-the-effectiveness-and-safety-of-dc-806-for-adults-with-moderate-to-severe-plaque-psoriasis\/."},{"key":"10.1016\/j.intimp.2025.115429_bb0255","unstructured":"A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis [Available from: https:\/\/clinicaltrials.gov\/study\/NCT04152382?intr=LY3509754&rank=2."},{"key":"10.1016\/j.intimp.2025.115429_bb0260","unstructured":"A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants [cited 2025 03\/02 at 5pm]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04586920?intr=LY3509754&rank=1."},{"key":"10.1016\/j.intimp.2025.115429_bb0265","unstructured":"A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis [Available from: https:\/\/trials.lilly.com\/en-US\/trial\/533216."},{"issue":"9","key":"10.1016\/j.intimp.2025.115429_bb0270","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/14712598.2021.1941862","article-title":"Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy","volume":"21","author":"Galluzzo","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2025.115429_bb0275","doi-asserted-by":"crossref","first-page":"adv00683","DOI":"10.2340\/actadv.v102.1993","article-title":"Safety of brodalumab in plaque psoriasis: integrated pooled data from five clinical trials","volume":"102","author":"Reich","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.intimp.2025.115429_bb0280","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2147\/CCID.S423234","article-title":"Effectiveness of brodalumab in patients with moderate-to-severe plaque psoriasis located in difficult-to-treat areas","volume":"16","author":"Cacciapuoti","year":"2023","journal-title":"Clin. Cosmet. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115429_bb0285","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.tips.2023.01.004","article-title":"Deucravacitinib (Sotyktu\u2122) for plaque psoriasis","volume":"44","author":"Granau","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2025.115429_bb0290","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/10600280231153863","article-title":"Deucravacitinib: the first FDA-approved Oral TYK2 inhibitor for moderate to severe plaque psoriasis","volume":"58","author":"Truong","year":"2024","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.intimp.2025.115429_bb0295","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/pharmaceutics16010023","article-title":"Phosphodiesterase-4 inhibition in the Management of Psoriasis","volume":"16","author":"Crowley","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.intimp.2025.115429_bb0300","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2147\/CCID.S266036","article-title":"Apremilast in the treatment of plaque psoriasis: differential use in psoriasis","volume":"15","author":"Gao","year":"2022","journal-title":"Clin. Cosmet. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115429_bb0305","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/jdv.18812","article-title":"Oral orismilast: efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets","volume":"37","author":"Warren","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115429_bb0310","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/bjd\/ljae507","article-title":"Orismilast, a phosphodiesterase 4B\/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS)","volume":"192","author":"Silverberg","year":"2025","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115429_bb0315","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2023.11.005","article-title":"Orismilast in moderate-to-severe psoriasis: efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)","volume":"90","author":"Warren","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115429_bb0320","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17010091","article-title":"Exploring the therapeutic landscape: a narrative review on topical and oral phosphodiesterase-4 inhibitors in dermatology","volume":"17","author":"Carmona-Rocha","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.intimp.2025.115429_bb0325","doi-asserted-by":"crossref","first-page":"13113","DOI":"10.2147\/IJN.S492180","article-title":"Topical application of dipyridamole and roflumilast combination nanoparticles loaded nanoemulgel for the treatment of psoriasis in rats","volume":"19","author":"Maded","year":"2024","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.intimp.2025.115429_bb0330","first-page":"30","article-title":"Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis\u2014a randomized controlled trial (PSORRO)","author":"Gyldenl\u00f8ve","year":"2023","journal-title":"Lancet Reg. Health \u2013 Europe"},{"key":"10.1016\/j.intimp.2025.115429_bb0335","unstructured":"ZORYVE [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215985s007lbl.pdf."},{"issue":"2","key":"10.1016\/j.intimp.2025.115429_bb0340","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3390\/ijms22020858","article-title":"Molecular aspects of pruritus pathogenesis in psoriasis","volume":"22","author":"Jaworecka","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115429_bb0345","unstructured":"Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis [Available from: https:\/\/clinicaltrials.gov\/study\/NCT03343639?cond=psoriasis&intr=serlopitant&rank=1."},{"key":"10.1016\/j.intimp.2025.115429_bb0350","article-title":"The role of co-signaling molecules in psoriasis and their implications for targeted treatment","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"22","key":"10.1016\/j.intimp.2025.115429_bb0355","doi-asserted-by":"crossref","first-page":"16095","DOI":"10.3390\/ijms242216095","article-title":"Inflammation and psoriasis: a comprehensive review","volume":"24","author":"Man","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115429_bb0360","article-title":"Current evidence on the role of lipid lowering drugs in the treatment of psoriasis","volume":"9","author":"Wang","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2025.115429_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107614","article-title":"Statins and autoimmunity: state-of-the-art","volume":"214","author":"Dehnavi","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"15","key":"10.1016\/j.intimp.2025.115429_bb0370","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3390\/healthcare12151526","article-title":"The impact of statins on disease severity and quality of life in patients with psoriasis: a systematic review and meta-analysis","volume":"12","author":"Aleid","year":"2024","journal-title":"Healthcare"},{"key":"10.1016\/j.intimp.2025.115429_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101523","article-title":"Targeting GM-CSF in inflammatory and autoimmune disorders","volume":"54","author":"Achuthan","year":"2021","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.intimp.2025.115429_bb0380","author":"Multi-Centre"},{"issue":"6","key":"10.1016\/j.intimp.2025.115429_bb0385","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/bjd.17195","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody","volume":"180","author":"Papp","year":"2019","journal-title":"Br. J. Dermatol."},{"issue":"15","key":"10.1016\/j.intimp.2025.115429_bb0390","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.3390\/jcm13154484","article-title":"Calcipotriol\/betamethasone dipropionate for the treatment of psoriasis: mechanism of action and evidence of efficacy and safety versus topical corticosteroids","volume":"13","author":"Gisondi","year":"2024","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.intimp.2025.115429_bb0395","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/09546634.2019.1707754","article-title":"Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries","volume":"32","author":"Balak","year":"2021","journal-title":"J. Dermatol. Treat."},{"issue":"6 Suppl 1","key":"10.1016\/j.intimp.2025.115429_bb0400","first-page":"S19","article-title":"Interleukin-17 inhibitor combination therapies for the treatment of psoriasis: a systematic review","volume":"15","author":"Martin","year":"2022","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"10.1016\/j.intimp.2025.115429_bb0405","unstructured":"Open Label Study, Evaluating Taltz in Combination With Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam in Psoriasis Patients [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04372277."},{"issue":"4","key":"10.1016\/j.intimp.2025.115429_bb0410","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1080\/15572536.2005.11832922","article-title":"Phylogenetic analysis of Ganoderma based on nearly complete mitochondrial small-subunit ribosomal DNA sequences","volume":"96","author":"Hong","year":"2004","journal-title":"Mycologia"},{"key":"10.1016\/j.intimp.2025.115429_bb0415","unstructured":"TREMFYA\u00ae (guselkumab) injection, for subcutaneous use 2017 [cited 2025 01\/02 at 10pm]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761061s009lbl.pdf."},{"issue":"3","key":"10.1016\/j.intimp.2025.115429_bb0420","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jaad.2024.10.076","article-title":"FRONTIER-2: a phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis","volume":"92","author":"Ferris","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115429_bb0425","doi-asserted-by":"crossref","first-page":"17515","DOI":"10.1038\/s41598-024-67371-5","article-title":"JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans","volume":"14","author":"Fourie","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2025.115429_bb0430","doi-asserted-by":"crossref","first-page":"7631","DOI":"10.2147\/IJN.S461514","article-title":"Recent advancements and trends of topical drug delivery systems in psoriasis: a review and bibliometric analysis","volume":"19","author":"An","year":"2024","journal-title":"Int. J. Nanomed."},{"issue":"4","key":"10.1016\/j.intimp.2025.115429_bb0435","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3390\/pharmaceutics16040449","article-title":"Recent approaches for the topical treatment of psoriasis using nanoparticles","volume":"16","author":"Bodn\u00e1r","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.intimp.2025.115429_bb0440","unstructured":"Otezla [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/otezla."},{"issue":"8","key":"10.1016\/j.intimp.2025.115429_bb0445","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1177\/10600280221137750","article-title":"A review of topical roflumilast for the treatment of plaque psoriasis","volume":"57","author":"Pixley","year":"2022","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.intimp.2025.115429_bb0450","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s43440-020-00206-y","article-title":"Pruritus in psoriasis and atopic dermatitis: current treatments and new perspectives","volume":"73","author":"Kahremany","year":"2021","journal-title":"Pharmacol. Rep."},{"issue":"8","key":"10.1016\/j.intimp.2025.115429_bb0455","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/13543784.2019.1638910","article-title":"The NK1 receptor antagonist serlopitant for treatment of chronic pruritus","volume":"28","author":"St\u00e4nder","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"10","key":"10.1016\/j.intimp.2025.115429_bb0460","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010848","article-title":"LFA-1\/ ICAM-1 promotes NK cell cytotoxicity associated with the pathogenesis of ocular toxoplasmosis in murine model","volume":"16","author":"Gao","year":"2022","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2025.115429_bb0470","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/metabo13040493","article-title":"Effects of hypolipidemic drugs on psoriasis","volume":"13","author":"Matwiejuk","year":"2023","journal-title":"Metabolites"},{"issue":"1","key":"10.1016\/j.intimp.2025.115429_bb0480","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190945","article-title":"GM-CSF in inflammation","volume":"217","author":"Hamilton","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2025.115429_bb0485","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.613975","article-title":"GM-CSF expression and macrophage polarization in joints of undifferentiated arthritis patients evolving to rheumatoid arthritis or psoriatic arthritis","volume":"11","author":"Fuentelsaz-Romero","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115429_bb0490","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2133.2010.09791.x","article-title":"A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol\/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study","volume":"163","author":"Tha\u00e7i","year":"2010","journal-title":"Br. J. Dermatol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115429_bb0495","doi-asserted-by":"crossref","first-page":"723","DOI":"10.36849\/JDD.2020.5300","article-title":"Fixed combination calcipotriene and betamethasone dipropionate (Cal\/BD) foam for beyond-mild psoriasis: a possible alternative to systemic medication","volume":"19","author":"Kircik","year":"2020","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.intimp.2025.115429_bb0500","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.biochi.2020.09.023","article-title":"Inhibition of interleukin-2-inducible T-cell kinase causes reduction in imiquimod-induced psoriasiform inflammation through reduction of Th17 cells and enhancement of Treg cells in mice","volume":"179","author":"Nadeem","year":"2020","journal-title":"Biochimie"},{"key":"10.1016\/j.intimp.2025.115429_bb0505","doi-asserted-by":"crossref","unstructured":"Xia X, Yu H, Li Y, Liang Y, Li G, Huang F. Transcriptome analysis identifies biomarkers for the diagnosis and management of psoriasis complicated with depression. Clin. Cosmet. Investig. Dermatol. 2023;16(null):1287-301.","DOI":"10.2147\/CCID.S413887"},{"issue":"1","key":"10.1016\/j.intimp.2025.115429_bb0510","first-page":"1","article-title":"Amygdalin alleviates psoriasis-like lesions by improving skin barrier function","volume":"317","author":"Wang","year":"2025","journal-title":"Arch. Dermatol. Res."},{"issue":"6","key":"10.1016\/j.intimp.2025.115429_bb0515","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/jdv.19811","article-title":"Efficacy and safety of piclidenoson in plaque psoriasis: results from a randomized phase 3 clinical trial (COMFORT-1)","volume":"38","author":"Papp","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115429_bb0520","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00403-024-03506-y","article-title":"Efficacy and safety of piclidenoson in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials","volume":"317","author":"Ul Haq","year":"2024","journal-title":"Arch. Dermatol. Res."},{"issue":"12","key":"10.1016\/j.intimp.2025.115429_bb0525","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.3390\/molecules27123680","article-title":"Drugs targeting the A3 adenosine receptor: human clinical study data","volume":"27","author":"Fishman","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.intimp.2025.115429_bb0530","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40257-021-00649-w","article-title":"New topical therapies for psoriasis","volume":"23","author":"L\u00e9","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115429_bb0540","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12944-023-01813-3","article-title":"Pathogenic sphingosine 1-phosphate pathway in psoriasis: a critical review of its pathogenic significance and potential as a therapeutic target","volume":"22","author":"Zhao","year":"2023","journal-title":"Lipids Health Dis."},{"issue":"20","key":"10.1016\/j.intimp.2025.115429_bb0545","doi-asserted-by":"crossref","first-page":"7488","DOI":"10.3390\/ijms21207488","article-title":"New treatment addressing the pathogenesis of psoriasis","volume":"21","author":"Tokuyama","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2025.115429_bb0550","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor\u2013modulating agent","volume":"84","author":"Bissonnette","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"24","key":"10.1016\/j.intimp.2025.115429_bb0555","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","article-title":"Phase 3 trials of tapinarof cream for plaque psoriasis","volume":"385","author":"Lebwohl","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2025.115429_bb0560","unstructured":"VATMA [Available from: https:\/\/www.vtama.com\/."},{"key":"10.1016\/j.intimp.2025.115429_bb0565","unstructured":"VTAMA (tapinarof) cream, for topical use [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215272s000lbl.pdf."},{"issue":"1","key":"10.1016\/j.intimp.2025.115429_bb0570","doi-asserted-by":"crossref","first-page":"11066","DOI":"10.1038\/s41598-021-90497-9","article-title":"Preclinical and clinical characterization of the ROR\u03b3t inhibitor JNJ-61803534","volume":"11","author":"Xue","year":"2021","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.intimp.2025.115429_bb0575","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jpha.2023.05.009","article-title":"Small molecule inhibitors of ROR\u03b3t for Th17 regulation in inflammatory and autoimmune diseases","volume":"13","author":"Zeng","year":"2023","journal-title":"J. Pharm. Anal."},{"issue":"9","key":"10.1016\/j.intimp.2025.115429_bb0580","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1093\/rheumatology\/kead022","article-title":"ROR\u03b3t inhibition ameliorates IL-23 driven experimental psoriatic arthritis by predominantly modulating \u03b3\u03b4-T cells","volume":"62","author":"Mortier","year":"2023","journal-title":"Rheumatology"},{"issue":"23","key":"10.1016\/j.intimp.2025.115429_bb0585","doi-asserted-by":"crossref","first-page":"21400","DOI":"10.1021\/acs.jmedchem.4c02318","article-title":"Discovery of novel N-sulfonamide-tetrahydroquinolines as potent retinoic acid receptor-related orphan receptor \u03b3t (ROR\u03b3t) inverse agonists for the treatment of psoriasis","volume":"67","author":"Lv","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2025.115429_bb0590","doi-asserted-by":"crossref","first-page":"9132","DOI":"10.1038\/s41598-021-88492-1","article-title":"Discovery of a novel ROR\u03b3 antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis","volume":"11","author":"Liu","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.intimp.2025.115429_bb0595","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s10787-023-01178-0","article-title":"Review of natural compounds for potential psoriasis treatment","volume":"31","author":"Elkhawaga","year":"2023","journal-title":"Inflammopharmacology"},{"issue":"6","key":"10.1016\/j.intimp.2025.115429_bb0600","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1007\/s13346-021-01031-3","article-title":"Natural medicine combined with nanobased topical delivery systems: a new strategy to treat psoriasis","volume":"12","author":"Zhao","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.115429_bb0605","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/jdv.16980","article-title":"Immunogenicity of biologic therapies in psoriasis: myths, facts and a suggested approach","volume":"35","author":"Tsakok","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2025.115429_bb0610","unstructured":"Amgevita [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/amgevita."},{"issue":"6","key":"10.1016\/j.intimp.2025.115429_bb0615","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/bjd.15857","article-title":"Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis","volume":"177","author":"Papp","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2025.115429_bb0620","unstructured":"Erelzi [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/erelzi."},{"issue":"4","key":"10.1016\/j.intimp.2025.115429_bb0625","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/bjd.15152","article-title":"The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis","volume":"176","author":"Griffiths","year":"2017","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115429_bb0630","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40262-021-01104-z","article-title":"Population pharmacokinetics of abrocitinib in healthy individuals and patients with psoriasis or atopic dermatitis","volume":"61","author":"Wojciechowski","year":"2022","journal-title":"Clin. Pharmacokinet."},{"issue":"10","key":"10.1016\/j.intimp.2025.115429_bb0635","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3390\/pharmaceutics13101539","article-title":"Does the vehicle matter? Real-world evidence on adherence to topical treatment in psoriasis","volume":"13","author":"Teixeira","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.intimp.2025.115429_bb0640","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/pharmaceutics17030283","article-title":"Topical therapy in psoriasis: clinical benefits, advances in novel drug delivery strategies, and gene therapy regimen","volume":"17","author":"Zhu","year":"2025","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.intimp.2025.115429_bb0645","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40257-022-00741-9","article-title":"Pharmacokinetics of roflumilast cream in chronic plaque psoriasis: data from phase I to phase III studies","volume":"24","author":"Thurston","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"issue":"10","key":"10.1016\/j.intimp.2025.115429_bb0650","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1111\/bcp.15364","article-title":"Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis","volume":"88","author":"Tran","year":"2022","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925014201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925014201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:49:04Z","timestamp":1772891344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925014201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":127,"alternative-id":["S1567576925014201"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115429","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing insights into psoriasis: from pathogenesis to current and emerging therapies","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115429"}}